Medicare Enrolled
Dr. Lorraine Snyder Dougherty, MD
Hematology & Oncology · Sellersville, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Snyder Dougherty from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Snyder Dougherty?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Snyder Dougherty
Dr. Lorraine Snyder Dougherty is a hematology & oncology specialist in Sellersville, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Snyder Dougherty performed 103,230 Medicare services across 1,954 unique beneficiaries.
Between the years covered by Open Payments, Dr. Snyder Dougherty received a total of $4,278 from 56 pharmaceutical and/or device companies across 199 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Snyder Dougherty is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in PA
$4,278 industry payments
Medicare Practice Summary
Medicare Utilization ↗103,230
Medicare services
Top 6% in PA for hematology & oncology
1,954
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,162 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
32,250 | $1 | $4 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
16,520 | $2 | $21 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
15,600 | $0 | $6 |
| Paclitaxel chemotherapy injection | 13,173 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 6,840 | $18 | $68 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,780 | $6 | $30 |
| Iron infusion (Monoferric) | 3,300 | $16 | $72 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,234 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,480 | $0 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,320 | $1 | $122 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
916 | $13 | $105 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
493 | $103 | $224 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
492 | $84 | $879 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
477 | $66 | $148 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
470 | $12 | $93 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
361 | $8 | $35 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
314 | $113 | $686 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
233 | $8 | $19 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
211 | $1 | $7 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
186 | $1 | $9 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
157 | $54 | $304 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
154 | $147 | $301 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
142 | $56 | $334 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
141 | $24 | $152 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
133 | $62 | $205 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
95 | $2 | $19 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
92 | $70 | $214 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
88 | $27 | $249 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
73 | $24 | $156 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
70 | $48 | $281 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
67 | $42 | $115 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
62 | $17 | $97 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
53 | $11 | $73 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
51 | $138 | $343 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
42 | $20 | $111 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
41 | $65 | $157 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
39 | $1 | $19 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
37 | $84 | $219 |
| New patient office visit, complex (60-74 min) | 30 | $180 | $432 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
13 | $109 | $297 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
35.4% high complexity
62.3% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,278
Total received (2018-2024)
Avg $611/year across 7 years
Top 37% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
56
Companies
199
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,141 (96.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$93 (2.2%)
Other
Charitable contributions, space rental, and other categories
$44 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$994
2023
$1,092
2022
$482
2021
$538
2020
$322
2019
$446
2018
$405
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$152
Novartis Pharmaceuticals Corporation
$102
PFIZER INC.
$100
Takeda Pharmaceuticals U.S.A., Inc.
$85
AstraZeneca Pharmaceuticals LP
$63
Janssen Biotech, Inc.
$62
GlaxoSmithKline, LLC.
$44
Incyte Corporation
$44
Integra LifeSciences Corporation
$38
Exact Sciences Corporation
$33
Astellas Pharma US Inc
$29
Daiichi Sankyo Inc.
$28
Regeneron Healthcare Solutions, Inc.
$26
Tempus AI, Inc
$25
Stemline Therapeutics Inc.
$25
Lilly USA, LLC
$24
Alexion Pharmaceuticals, Inc.
$23
Celgene Corporation
$22
SpringWorks Therapeutics, Inc.
$22
JAZZ PHARMACEUTICALS INC.
$19
Genmab U.S., Inc.
$14
Merck Sharp & Dohme LLC
$13
Top 3 companies account for 35.6% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$258
Incyte Corporation
$235
Genentech USA, Inc.
$200
AstraZeneca Pharmaceuticals LP
$199
ABBVIE INC.
$189
Daiichi Sankyo Inc.
$182
Amgen Inc.
$180
E.R. Squibb & Sons, L.L.C.
$162
PFIZER INC.
$159
Celgene Corporation
$156
EISAI INC.
$135
Astellas Pharma US Inc
$133
Takeda Pharmaceuticals U.S.A., Inc.
$129
Merck Sharp & Dohme LLC
$112
Lilly USA, LLC
$107
Novartis Pharmaceuticals Corporation
$102
GlaxoSmithKline, LLC.
$100
Boehringer Ingelheim Pharmaceuticals, Inc.
$97
Bayer HealthCare Pharmaceuticals Inc.
$85
Merck Sharp & Dohme Corporation
$83
Pharmacyclics LLC, an AbbVie Company
$75
Seagen Inc.
$65
Stemline Therapeutics Inc.
$61
GENZYME CORPORATION
$59
JAZZ PHARMACEUTICALS INC.
$58
Genmab U.S., Inc.
$56
TerSera Therapeutics LLC
$56
Deciphera Pharmaceuticals Inc.
$53
Kyowa Kirin, Inc.
$53
Welch Allyn
$44
Seattle Genetics, Inc.
$44
Regeneron Healthcare Solutions, Inc.
$43
Eisai Inc.
$41
Bayer Healthcare Pharmaceuticals Inc.
$40
Integra LifeSciences Corporation
$38
Dendreon Pharmaceuticals LLC
$38
Pharmacyclics LLC, An AbbVie Company
$35
Alnylam Pharmaceuticals Inc.
$34
Exact Sciences Corporation
$33
BeiGene USA, Inc.
$27
AbbVie Inc.
$27
Tempus AI, Inc
$25
SOBI, INC
$24
AVEO Pharmaceuticals, Inc.
$24
Exelixis Inc.
$23
Alexion Pharmaceuticals, Inc.
$23
SpringWorks Therapeutics, Inc.
$22
Blueprint Medicines Corporation
$21
Blue Earth Diagnostics Limited
$21
Progenics Pharmaceuticals, Inc.
$20
TESARO, Inc.
$19
Servier Pharmaceuticals LLC
$17
Karyopharm Therapeutics Inc.
$17
Rigel Pharmaceuticals, Inc.
$15
Myriad Genetic Laboratories, Inc.
$15
Gilead Sciences, Inc.
$12
Top 3 companies account for 16.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · Aliqopa · Axumin · BLENREP · BRUKINSA · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · CODMAN CERTAS · CYRAMZA · Cologuard Collection Kit · DARZALEX · Doptelet · ELAHERE · ELIQUIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · FOTIVDA · FRUZAQLA · Fabhalta · GAVRETO · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · INJECTAFER · INLYTA · INREBIC · Inrebic · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · NINLARO · None · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · POLIVY · POTELIGEO · PREVYMIS · PROVENGE · PYLARIFY · Padcev · Pomalyst · Poteligeo · PreciseTumor · QINLOCK · QUZYTTIR · REBLOZYL · Revlimid · Rituxan Hycela · SARCLISA · SPRYCEL · Stivarga · TAGRISSO · TALVEY · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Tivdak · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · XPOVIO · XTANDI · Xermelo · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
120
Per 100K population
18.6
County median income
$111,951
Nearest hospital
ST LUKE'S HOSPITAL - GRAND VIEW CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Snyder Dougherty is a mixed practice specialist, with above-average Medicare volume (top 6% in PA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Snyder Dougherty experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Snyder Dougherty performed 32,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Snyder Dougherty receive payments from pharmaceutical companies?
Yes. Dr. Snyder Dougherty received a total of $4,278 from 56 companies across 199 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Snyder Dougherty's costs compare to other hematology & oncology specialists in Sellersville?
Dr. Snyder Dougherty's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Snyder Dougherty) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Sellersville
Browse hematology & oncology specialists in Sellersville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology